Diabetes Reversal and the Subgingival Microbiota
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Renee Tangi
- Phone Number: 215-888-4045
- Email: pdm-bariatricsurgery@upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Temple University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women undergoing bariatric surgery who are 25-65 years old.
- BMI > 35 kg/m2.
- Diabetic subjects: HbA1c> 6.0% or fasting plasma glucose >126 mg/dl).
- Normoglycemic subjects: HbA1c<5.75% or fasting plasma glucose <100 mg/dl).
- Dental criteria: Minimum of 4 posterior teeth.
- Signed and dated informed consent form.
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Subjects diagnosed with type 1 diabetes, maturity onset diabetes of the young (MODY), or latent autoimmune diabetes in adults (LADA).
- Women who are considering pregnancy or are currently breastfeeding.
- Individuals with a history of chronic inflammatory or autoimmune diseases or taking medications that affect immune function or affect body weight such as chronic systemic steroids.
- Currently smoke more than 10 cigarettes per day.
- Periodontal treatment within 3 months of bacterial sampling.
- Acute periodontal infection (abscess) within 1 month of bacterial sampling or abscess in teeth or adjacent teeth within 1 month of sampling.
- Treatment with antibiotics within one month of sample collection (except as part of the surgical regimen of prophylactic antibiotic immediately prior to surgery).
- A treatment regimen of steroids within 1 month of sample collection.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Diabetic patients
Diabetic patients who plan to undergo bariatric surgery
|
Blood, plaque, and other oral samples
|
|
Normo-glycemic (non-diabetic) patients
Non-diabetic patients who plan to undergo bariatric surgery
|
Blood, plaque, and other oral samples
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bacterial composition
Time Frame: 18 months
|
as determined by 16s rRNA community profiling
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bacterial mRNA profiling
Time Frame: 18 months
|
RNA will be isolated then amplified by the MessageAmp II bacterial RNA amplification kit (Ambion/Life Technologies).
Ribosomal RNA will be depleted with the RiboZero human/mouse and meta bacterial kits (Epicentre/Illumina) and human mRNA will be depleted with oligo(dT).
Illumina sequencing libraries will be constructed with the Illumina TruSeq RNA kit and assessed with an Illumina HiSeq instrument.
|
18 months
|
|
Gingival inflammation
Time Frame: 18 mos.
|
samples will be assessed for inflammatory cytokines (e.g.
IL-1β, IL-17 or TNF) by multiplex assay or ELISA assay
|
18 mos.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dana Graves, DDS, DMSc, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 825975
- 1R01DE026603-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.